Adeno-associated virus capsid antigen presentation is dependent on endosomal escape by Li, Chengwen et al.
Research article
1390 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 3   March 2013
Adeno-associated virus capsid  
antigen presentation is dependent  
on endosomal escape
Chengwen Li,1,2 Yi He,1,3 Sarah Nicolson,1,4 Matt Hirsch,1 Marc S. Weinberg,1  
Ping Zhang,1 Tal Kafri,1,5 and R. Jude Samulski1,4
1Gene Therapy Center and 2Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.  
3Hematopoietic Stem Cell Transplantation Center, Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China.  
4Department of Pharmacology and 5Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Adeno-associated virus (AAV) vectors are attractive for gene delivery-based therapeutics, but data from recent 
clinical trials have indicated that AAV capsids induce a cytotoxic T lymphocyte (CTL) response that eliminates 
transduced cells. In this study, we used traditional pharmacological agents and AAV mutants to elucidate the 
pathway of capsid cross-presentation in AAV-permissive cells. Endosomal acidification inhibitors blocked 
AAV2 antigen presentation by over 90%, while proteasome inhibitors completely abrogated antigen presenta-
tion. Using mutant viruses that are defective for nuclear entry, we observed a 90% decrease in capsid antigen 
presentation. Different antigen presentation efficiencies were achieved by selectively mutating virion nuclear 
localization signals. Low antigen presentation was demonstrated with basic region 1 (BR1) mutants, despite 
relatively high transduction efficiency, whereas there was no difference in antigen presentation between BR2 
and BR3 mutants defective for transduction, as compared with wild-type AAV2. These results suggest that 
effective AAV2 capsid antigen presentation is dependent on AAV virion escape from the endosome/lysosome 
for antigen degradation by proteasomes, but is independent of nuclear uncoating. These results should facil-
itate the design of effective strategies to evade capsid-specific CTL-mediated elimination of AAV-transduced 
target cells in future clinical trials.
Introduction
Adeno-associated virus (AAV) is a single-stranded DNA virus 
with a genome composed of the rep and capsid genes flanked by 
2 inverted terminal repeats. AAV vectors have been successfully 
used in several clinical trials in patients with Leber congenital 
amaurosis and hemophilia B (1–6). Gene delivery using AAV vec-
tors is attractive due to their ability to transduce dividing and 
nondividing cells, their ease of production, their long-term trans-
genic expression, and their lack of pathogenicity. AAV vectors 
are constructed by substituting the rep and capsid genes with 
therapeutic ones. Since there are no viral genes in AAV vectors, 
it has been postulated that cellular immune responses to AAV 
may be low. However, recent data from a clinical trial suggested 
that AAV capsid–specific cytotoxic T lymphocytes (CTLs) may 
eliminate AAV-transduced target cells. In 1 patient with hemo-
philia B, therapeutic protein levels were obtained 4 weeks after 
liver transduction of an AAV serotype 2 (AAV2) vector encoding 
coagulation factor IX (F9). Unexpectedly, however, the F9 levels 
remained high for only 2 weeks, and then declined back to basal 
levels, with concomitant elevation of liver transaminases, indi-
cating liver damage caused by a CTL immune response. Further 
experiments have suggested that a capsid-specific CTL response 
contributed to this outcome (5, 6).
Indeed, in mouse models, using an adenovirus vector to deliver 
the AAV capsid, direct intramuscular delivery of AAV, or applica-
tion of AAV vector–pulsed dendritic cells (7–9) can elicit a CTL 
response against the AAV capsid. These results indicate that AAV 
capsid antigen can be presented via both classical antigen presen-
tation and cross-presentation pathways. In humans and primates, 
it has been demonstrated that a capsid-specific CTL response is 
induced from natural AAV2 infection based on a sensitive IFN-γ 
ELISPOT analysis (10).
Antigen cross-presentation from exogenous protein has been 
intensively studied in professional APCs. Two distinct working 
models for the cross-presentation of exogenous antigens on 
MHC class I molecules have been proposed (11). The first path-
way (cytosolic pathway) utilizes the classical endogenous anti-
gen-processing machinery to generate antigenic peptides. After 
exogenous protein is taken up by endocytosis, antigen makes 
its way into the cytosol where it is degraded by the proteasome 
before being translocated into the ER by the transporter asso-
ciated with antigen presentation (TAP). In the ER, the peptide 
antigen is loaded onto nascent MHC I molecules to form anti-
gen-MHC I complexes which are then presented on the cell sur-
face to activate CD8+ T cells (12). In the second pathway (vacu-
olar or endosomal pathway), endocytosed antigen is processed 
independently of the proteasome and the TAP. The protein is 
degraded by proteases within the endosomal-lysosomal sys-
tem and loaded onto recycled MHC I molecules, similar to the 
MHC class II antigen presentation pathway (13, 14). Although 
AAV-transduced hepatocytes are killed by capsid-specific CTLs 
with identical MHC class I alleles, and proteasome inhibition 
protects target cell killing by these CTLs (5, 15), no detailed stud-
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ies have been carried out to determine the mechanism of AAV 
capsid antigen cross-presentation in AAV2-transduced cells.
AAV transduction involves several steps, including AAV binding 
on the target cell surface, receptor-mediated endocytosis into an 
endosome and lysosome, perinuclear accumulation, entrance into 
and uncoating within the nucleus, and second-strand synthesis 
before transgenic expression (16–18). AAV2 infection requires 
heparan sulfate proteoglycan (HSPG) as a primary receptor, 
together with coreceptors which include FGF receptors, integrin 
receptors, laminin receptors, or HGF receptors for optimal attach-
ment (19–24). Following attachment to cell surface receptors, 
AAV2 internalization occurs via a receptor-mediated endocytotic 
mechanism. The process of endocytosis is clathrin and dynamin 
dependent (25, 26). Endosomal acidification is necessary for effec-
tive AAV2 infection. In the endocytic system, AAV2 virion is traf-
ficked to lysosomes through early endosomes, late endosomes, 
and recycling endosomes (17, 26). In the acidic environment, the 
AAV2 virion undergoes a conformational change to expose several 
domains in VP1 and/or VP2 N-termini, which are buried inside the 
capsid of the intact virion. Several domains assist the AAV2 virion 
to escape from the endosomal-lysosomal system and travel to the 
nucleus (27–31). These include a phospholipase A2 (PLA2) motif 
and 3 basic regions (BR1, 2, and 3), all of which putatively con-
trol endosomal escape, nuclear localization, and nuclear import 
via the nuclear pore complex, respectively (27–31). AAV2 particles 
have also been found to accumulate in the Golgi complex (32). 
It is generally accepted that AAV2 virion uncoating occurs in the 
nucleus where gene expression is then induced (18, 31). However, 
it remains unknown which organelles are responsible for gener-
ation of AAV2 capsid antigens. In this study, we applied classical 
pharmacological inhibitors to block different pathways of anti-
gen processing and presentation in AAV2-transduced target cells 
and demonstrated that antigen presentation by AAV2 capsids is 
proteasome dependent. More importantly, using AAV2 mutants, 
which result in differential organelle trapping of virions after 
infection, we demonstrated that effective AAV2 capsid antigen pre-
sentation requires escape from the endosomal-lysosomal system 
and encapsidation of AAV2 genomes, independent of intact virion 
uncoating in the nucleus.
Results
Inhibition of endosomal acidification decreases AAV capsid antigen pre-
sentation. To investigate the mechanism of AAV capsid antigen 
presentation and its relationship with AAV virion uncoating and 
degradation, we established a novel system by introducing a strong 
immune domain into the AAV2 capsid for detection of antigen-spe-
cific CTL activation in AAV2-permissive cells. OVA SIINFEKL 
peptide was used to replace the HI loop of AAV2 and maintained 
Figure 1
Efficient antigen presentation from 
AAV2-OVA transduction in a HepG2/H-
2Kb cell line. HepG2/H-2Kb cells (2 × 105 
cells) were seeded on a 12-well plate 
for 30 minutes, and then 2 × 1010 par-
ticles of AAV2/AAT or AAV2-OVA/AAT 
vectors were added. Additionally, 10 μg 
of peptides (OVA peptide SIINFEKL 
or p18) was also added as a control. 
After 24-hour transduction, the cells 
were fixed and washed 4 times with 
PBS, then incubated with 1 × 106 OT-1 
spleen cells overnight. OT-1 cells were 
harvested and stained with FITC-CD69 
and PE-CD8 antibodies, and the CD69 
and CD8 double-positive cells were 
analyzed by flow cytometry. (A) Flow 
cytometric histograms of OT-1 CD8 
activation by AAV2-OVA–transduced 
HepG2/H-2Kb cells. (B) Effective OVA 
SIINFEKL antigen presentation in 
HepG2/H-2Kb cells after AAV2-OVA 
transduction. Data represent the aver-
age and standard deviations from 4 
individual experiments. **P < 0.01 when 
compared with AAV2 treatment.
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a similar capacity to package the AAV2 virion and transduce cells, 
as compared with wild-type AAV2 (33). We established HepG2/
H-2Kb and 293/H-2Kb cell lines by infection of lentivirus vector 
lenti/H-2Kb, which encodes the H-2Kb transgene (Supplemental 
Figure 1; supplemental material available online with this article; 
doi:10.1172/JCI66611DS1). To address whether the OVA SIINFEKL 
peptide was processed and presented on the surface of HepG2/H-2Kb 
with H-2Kb molecules after AAV2-OVA infection, we transduced 
HepG2/H-2Kb cells by AAV2-OVA/AAT or AAV2/AAT viruses. 
Additionally, the OVA-derived SIINFEKL peptide and p18 from 
an alternative ORF of human coagulation factor IX cDNA were 
used to pulse HepG2/H-2Kb cells (34). Twenty-four hours later, 
HepG2/H-2Kb cells were fixed and washed thoroughly, and OT-1 
spleen cells were added to HepG2/H-2Kb cells overnight. The 
activation of OT-1 spleen cells was detected by flow cytometry 
for expression of CD8 and the early activation marker CD69. As 
shown in Figure 1, the p18 peptide–pulsed cells did not activate 
OT-1 cells, but OVA SIINFEKL peptide treatment led to 70% CD8/
CD69 double positivity. We observed no activation of OT-1 cells 
from AAV2/AAT transduction, similar to control and peptide p18 
treatment (0.3%, 0.36%, and 0.37% of activated OT-1 cells, respec-
tively). In contrast, AAV2-OVA/AAT transduction induced 5.8% of 
activated OT-1 cells (Figure 1). This indicates that the SIINFEKL 
epitope from AAV2-OVA vector transduction can be processed and 
presented on the cell surface with H-2Kb molecules and can acti-
vate CTLs. Previous studies have shown that acid neutralization 
in the endosomes inhibits AAV transduction (26), and we verified 
that such acid neutralization does not influence AAV entry (Sup-
plemental Figure 2). To address whether inhibition of acidification 
in the endosomes affects antigen presentation by the AAV capsid 
after AAV transduction, we incubated HepG2/H-2Kb cells with 
ammonium chloride or chloroquine for 1 hour before AAV2-OVA 
vector was added at 105 per cell, since the efficiency of AAV capsid 
antigen presentation was dose dependent (Figure 2, A and B). After 
24 hours of AAV transduction, the cells were fixed and washed. 
The spleen cells from OT-1 mice were cocultured with AAV2-OVA–
transduced HepG2/H-2Kb cells overnight, and activated OT-1 
spleen cells were detected by flow cytometry. The concentrations 
of ammonium chloride and chloroquine used in this experiment 
were not toxic to HepG2 cells (Figure 3A). Consistent with prior 
work, both ammonium chloride and chloroquine inhibited AAV2 
transduction (Figure 3B) (26). Compared with antigen presenta-
tion from AAV2-OVA transduction without treatment, over 90% 
inhibition of antigen presentation was observed in the groups 
treated with ammonium chloride and chloroquine (Figure 3, C 
and D). In the endosome-lysosome system, protein is degraded 
by proteases, especially cathepsins. To analyze the participation 
of proteases in the processing of AAV capsid after transduction, 
we tested 2 different protease inhibitors: leupeptin H (an inhib-
itor of serine and cysteine proteases, including cathepsin B), and 
pepstatin A (an inhibitor of aspartate proteases, including cathep-
sins D and E) (35, 36). Incubation of HepG2/H-2Kb with AAV2-
OVA vector in the presence of leupeptin and pepstatin partially 
blocked OVA presentation, while no cell toxicity was observed 
(Figure 3, C and E), suggesting that OVA antigen processing from 
AAV2-OVA virion required the participation of some proteases. 
In disagreement with the results from Akache’s study (37), we 
did not find that protease inhibitors had enhanced function in 
AAV transduction (Figure 3B), perhaps because different protease 
inhibitors or cellular targets were used (37).
AAV capsid antigen presentation is dependent on proteasomal degrada-
tion. The proteasome is a multisubunit complex responsible for the 
complete degradation of many cellular proteins. In addition to its 
critical role in a variety of biological processes, the proteasome is 
also required for degradation of proteins to generate antigens for 
presentation to CTLs via the MHC class I pathway. To evaluate 
whether proteasomal degradation participates in AAV capsid anti-
gen processing, we treated HepG2/H-2Kb cells with 2 proteasome 
inhibitors: MG132 and bortezomib. As with many previous stud-
ies (38), both proteasome inhibitors enhanced AAV2 transduction 
in HepG2 cells (Figure 3B). However, OVA antigen presentation 
by HepG2/H-2Kb cells incubated with AAV2-OVA vector in the 
presence of these inhibitors was completely diminished (Figure 3, 
C and F). This result indicates that AAV2-OVA virions or derived 
peptides translocate to the cytosol of HepG2/H-2Kb cells and are 
degraded by the proteasomes.
Figure 2
Capsid antigen presentation in AAV2-OVA–transduced HepG2/H-2Kb 
cells. (A) Dose response of antigen presentation. HepG2/H-2Kb cells 
(2 × 105 cells) were seeded on a 12-well plate, then infected with 
AAV2-OVA/AAT virus at different doses. Forty-eight hours later, 1 × 106 
spleen cells from OT-1 mice were added to cell culture overnight. 
The number of cells expressing CD8 and CD69 were detected by 
flow cytometry. (B) Time course of antigen expression. After HepG2/ 
H-2Kb cells were plated, 1 × 105 particles of AAV2-OVA/AAT vector 
per cell were added to the culture medium. At different time points 
after AAV transduction, HepG2/H-2Kb cells were fixed with 1% 
paraformaldehyde in PBS and washed thoroughly. After incubation 
with OT-1 spleen cells, the activation of OT-1 spleen cells was detected 
by flow cytometry for expression of CD8 and CD69.
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Tripeptidyl peptidase II is involved in AAV capsid antigen presentation. In 
addition to the proteasome, the cytosolic protease tripeptidyl pep-
tidase II (TPPII) has been implicated in MHC class I antigen presen-
tation. TPPII is the largest known multifunctional eukaryotic pep-
tidase (39). In addition to its housekeeping function in intracellular 
protein degradation, TPPII also plays a role in several vital cellu-
lar processes including antigen processing (40). The chemical 
inhibitor of TPPII, AAF-MCK, led to approximately 50% block-
ing of antigen presentation by AAV2-OVA–transduced HepG2/ 
H-2Kb cells, but without effect on cell toxicity or transduction effi-
ciency (Figure 3, A–C, and H).
AAV2 capsid antigen processing is sensitive to brefeldin A. Brefeldin A 
(BFA) inhibits the transport of proteins from the ER to the Golgi com-
plex and blocks the secretion of newly synthesized proteins (41, 42). 
In this study, we used BFA to determine whether antigen process-
ing and presentation from AAV2-OVA–infected cells was related to 
the transport of processed peptides through the Golgi complex to 
the HepG2/H-2Kb cell membrane. BFA significantly suppressed 
AAV2 transduction (Figure 3B), and incubation of HepG2/H-2Kb 
cells with BFA inhibited antigen presentation from AAV2-OVA 
transduction by nearly 100% (Figure 3, C and G). This strongly sug-
gests that AAV2-OVA–derived peptides are transported to the cell 
surface through the Golgi complex after translocation to the ER.
Endosomal/lysosomal escape plays a role in AAV capsid antigen presenta-
tion. Major domains on the N termini of VP1 and VP2 in the capsid 
are necessary for AAV subcellular traveling. During infection (prior 
to endosomal/lysosomal escape), a conformational change pro-
motes exposure of these motifs on the surface of the capsid (27–31). 
Several functional motifs have been identified: a PLA2 domain and 
putative nuclear localization signals (NLSs) BR1, BR2, and BR3. 
Phospholipase plays a role in disrupting the membrane of a vesic-
ular compartment and allows for viral escape from the endosome/ 
Figure 3
The effect of inhibitors on capsid antigen cross-presentation in HepG2/H-2Kb cells. (A) Toxicity of inhibitors on HepG2/H-2Kb cells. HepG2/H-2Kb 
cells (2 × 105 cells) were seeded on 12-well plates and incubated with different inhibitors. Cell viability was measured 24 hours later. (B) Effect of 
inhibitors on AAV2 transduction in HepG2/H-2Kb cells. HepG2/H-2Kb cells were incubated with inhibitors for 1 hour, then 1 × 104 particles per 
cell of AAV2-OVA/luc vector were added to the culture for 24 hours. Cells were harvested for luciferase analysis. *P < 0.05 and **P < 0.01 when 
compared with AAV2/luc transduction without drug treatment. (C) Effect of inhibitors on antigen presentation. HepG2/H-2Kb cells were incubated 
with inhibitors for 1 hour and then transduced with 2 × 1010 AAV2-OVA/AAT vector for 24 hours. Cells were then fixed with 1% paraformaldehyde 
and washed, and OT-1 spleen cells were added to HepG2/H-2Kb cell culture medium. Activation of OT-1 spleen cells was determined by flow 
cytometry detecting CD8 and CD69 expression. The inhibition of antigen presentation was calculated as: [1-(number of activated OT-1 cells in 
inhibitor group with AAV2-OVA infection minus background group without AAV2-OVA infection)/(number of activated OT-1 cells in the group with 
AAV2-OVA infection – background group)] × 100%. *P < 0.05 and P < 0.01 when compared with the AAV2-OVA group without treatment. Data 
represent the average of 4 individual experiments and standard deviations. (D–H) Representative data from 1 experiment for acidification inhibitor 
(D), protease inhibitor (E), proteasome inhibitor (F), Golgi transporter inhibitor (G), and TPPII inhibitor (H).
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lysosome into the cytosol. It has been demonstrated that a mutant 
with a 2-residue substitution of PLA2 (AAV2/75HD/AN) is unaf-
fected with regard to cell surface binding capacity or viral endocy-
tosis, but has greatly attenuated PLA2 activity and compromised 
viral infectivity (27, 31). To further confirm the role of AAV endo-
somal/lysosomal escape in capsid antigen presentation, we incu-
bated AAV2-OVA/75HD/AN vectors with HepG2/H-2Kb cells. 
Twenty-four hours later, the HepG2/H-2Kb cells were washed 
and then incubated with OT-1 spleen cells for another 24 hours, 
and activated OT-1 T cells were measured by flow cytometry. As 
shown in Figure 4, compared with the AAV2-OVA vector, a sig-
nificant reduction in antigen presentation was observed with the 
AAV2-OVA/75HD/AN mutant vector (Figure 4B and Supple-
mental Figure 3). Similar to prior findings, the PLA2 mutant 
showed decreased AAV transduction (Figure 4A). Our previous 
study demonstrated that a VP3-only virus, which does not con-
tain the PLA2 domain on its N-terminus, is also unable to enter 
the nucleus and fails to transduce AAV2-permissive cells. Similar 
to the AAV2-OVA/75HD/AN mutant, infection with AAV2-OVA 
VP3–only virus led to reduced antigen presentation by HepG2/ 
H-2Kb cells (Figure 4 and Supplemental Figure 3).
Modification of AAV capsid NLSs impacts antigen presentation. Three 
potential NLSs on the AAV capsid protein N-termini of VP1 and 
VP2 have been identified, namely, BR1 (only in VP1), BR2, and BR3 
(in VP1 and VP2); these NLSs are comprised of hydrophilic, basic 
regions (also considered basic clusters) (29–31). We have demon-
strated that mutation of these regions dramatically decreases 
transduction as a result of defective nuclear entry of the mutant 
virus (30). An imaging study of AAV2 trafficking has shown that 
the BR1 mutant localizes mainly to the Golgi complex, whereas 
BR2 and BR3 mutants display a diffused localization, distal from 
the nucleus after infection (30). To understand the relationship 
between AAV capsid antigen presentation and uncoated AAV capsid 
degradation localized within organelles, we integrated the OVA 
SIINFEKL peptide into NLS mutants by substitution of the HI 
loop. Similar to our prior result, compared with AAV2-OVA vector, 
the OVA integration mutants reduced the transduction efficiency of 
BR1, BR2, and BR3 mutants by 4-, 100-, and 2,000-fold (Figure 5A), 
respectively. Next, we infected HepG2/H-2Kb cells with these 
Figure 4
Mutation of the PLA domain and VP3-only virus reduces AAV capsid 
antigen presentation. (A) Transgenic expression from an AAV2/75HD/
AN mutant and VP3-only viruses in HepG2 cells. HepG2 cells (1 × 105 
cells) were seeded in 24-well plates, and 1 × 109 particles of AAV/
luc virus (AAV2, AAV2/75HD/AN, and VP3-only) were added to cell 
culture medium. After incubation for 24 hours, luciferase expression in 
AAV-transduced HepG2 cells was measured. **P < 0.01 when com-
pared with AAV2. (B) Antigen presentation by transduced AAV2-OVA, 
75HD/AN, and VP3-only virus. Particles (2 × 1010 particles) of AAV2-
OVA viruses (AAV2-OVA, AAV2-OVA/75HD/AN, and AAV2-OVA/VP3-
only) were incubated with 2 × 105 HepG2/H-2Kb cells for 24 hours, after 
which unbound virus was washed out. Spleen cells (1 × 106 cells) from 
OT-1 mice were added to HepG2/H-2Kb culture medium and incubated 
overnight. Reduction of antigen presentation by the PLA mutant and 
transduced VP3-only virus were calculated as described in Methods. 
**P < 0.01 when compared with AAV2-OVA. Data are based on the 
average and standard deviations from 3 individual experiments.
Figure 5
Effect of AAV NLSs on capsid antigen presentation. (A) Transgenic 
expression from transduction with 3 NLS mutants. HepG2 cells were 
transduced with 3 AAV mutants (BR1, BR2, and BR3) at 1 × 104 parti-
cles per cell. Twenty-four hours later, AAV-based luciferase expression 
was measured. **P < 0.01 when compared with AAV2. (B) Antigen 
presentation by transduced NLS mutants. HepG2/H-2Kb cells were 
transduced with NLS mutant vectors at 1 × 105 particles per cell for 
24 hours. Cells were washed and incubated with 1 × 106 spleen cells 
of OT-1 mice overnight. Activation of CD8 T cells was detected by flow 
cytometry. **P < 0.01 when compared with AAV2-OVA. Data represent 
the average and standard deviations from 3 individual experiments.
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mutants and examined antigen presentation on the cell surface. 
BR1 mutant infection led to significantly decreased antigen pre-
sentation. Interestingly, both BR2 and BR3 mutants induced anti-
gen presentation similar to that induced by the AAV2-OVA vector 
(Figure 5 and Supplemental Figure 4). The result, combined with 
transduction efficiency, suggests that uncoating in the nucleus is 
not required for AAV capsid antigen presentation after infection.
Effective AAV capsid antigen presentation is dependent on the encapsida-
tion of the AAV genome. AAV vectors purified from CsCl have been 
applied in clinical trials, however this purification approach is not 
scalable. Recently, ion exchange chromatography has been stud-
ied to purify AAV vectors (43–46). Unlike the CsCl purification 
approach, the chromatographic method cannot currently sepa-
rate genome-containing particles of AAV vectors (full particles) 
from empty virions because the virion surfaces are the same. The 
contamination of empty virions inhibits transduction from full 
particles of AAV vectors and potentially increases the virus capsid 
antigen load in transduced cells (46). To investigate the possibility 
of antigen presentation by empty particles, we made empty AAV 
vector by transfecting only 2 plasmids (pXX6-80 and pXR2OVA) 
instead of using 3 plasmids for AAV vector production. Virus titer 
was quantitated by Western dot-blot analysis with monoclonal 
antibody A20, which only recognizes intact AAV virion. The same 
particles of empty and full AAV2-OVA vectors were used to infect 
HepG2/H-2Kb cells to determine their antigen presentation capac-
ity. Unexpectedly, despite the similarity of components (composi-
tion of VP1, VP2, VP3, PLA2, and NLS motifs) in empty and full 
particle virions of AAV vectors, significantly less antigen presenta-
tion by empty virions was induced than was the case with genome-
containing full particles (Figure 6). This result indicates that 
encapsidation of the AAV genome in AAV virions helps with AAV 
uncoating for proteasomal degradation. Generally in recombinant 
AAV preparations, most vector lots are a mixture of full and empty 
particles. To elucidate whether full particles have an effect on anti-
gen presentation by empty capsids, we transduced HepG2/H-2Kb 
cells with the mixture of AAV2/AAT and empty OVA vectors and 
examined the activation of OT-1 spleen cells after incubation with 
the infected HepG2/H-2Kb cells. The incubation of AAV2/AAT vec-
tor with AAV2-OVA full particles inhibited AAV2-OVA capsid anti-
gen presentation by 50%–60% (Figure 6C and Supplemental Figure 
5). However, HepG2/H-2Kb cells transduced with AAV2/AAT and 
empty OVA vectors only induced 0.36% of the OT-1 CD8CD69–
activated cells, similar to the result seen in HepG2/H-2Kb 
cells treated with AAV2/AAT, empty OVA capsids, or control 
(0.22%, 0.28%, and 0.46%, respectively) (Figure 6C and Supplemen-
tal Figure 5). This result suggests that wild-type AAV2 may not res-
cue AAV capsid antigen presentation by empty virions.
Proteasome-dependent degradation of AAV capsid in other cells. We 
demonstrate that AAV-transduced capsid antigen presentation is 
proteasomal degradation dependent in the human liver HepG2 
Figure 6
Capsid antigen cross-presentation from empty virus infection. HepG2/H-2Kb cells (2 × 105 cells) were transduced with 1 × 105 particles per cell of 
empty virus for 24 hours. Cells were then washed and incubated with OT-1 spleen cells overnight. The activation of CD8 T cells was detected by 
flow cytometry. (A) Graphs are representative data sets from 1 experiment. (B) Decreased antigen presentation from empty virion transduction. 
**P < 0.01 when compared with AAV2-OVA. (C) No effect of AAV2 full particles on antigen presentation by empty OVA capsids. HepG2/H-2Kb 
cells (2 × 105 cells) were transduced with AAV2/AAT and AAV2-OVA or empty OVA virus at 5 × 104 particles per cell for each virus for 24 hours. 
Activation of OT-1 spleen cells was detected after incubation of OT-1 cells with AAV-treated HepG2/H-2Kb cells. **P < 0.01 when compared with 
AAV2-OVA. Data are based on the average and SD from 4 individual experiments.
research article
1396 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 3   March 2013
cell line (described above). We hypothesized that a proteasome-de-
pendent degradation pathway may also apply to other AAV2-per-
missive cells from different origins. Two other cell lines — 293/
H-2Kb and Cos-7/H-2Kb — were tested for this purpose. After 
1-hour incubation of 293/H-2Kb and Cos-7/H-2Kb cells with 
the proteasome inhibitor bortezomib, AAV2-OVA vectors were 
added to cell culture. Twenty-four hours later, the cells were fixed 
and cocultured with OT-1 spleen cells overnight, and thereafter 
CD8/CD69–expressing T cells were detected by flow cytometry. 
As shown in Figure 7, and consistent with results in the HepG2 
cells, bortezomib completely inhibited antigen presentation by 
both AAV2-OVA–transduced 293 and Cos-7 cell lines (Supple-
mental Figure 6). Similar to prior studies, proteasome inhibitors 
enhanced AAV2 transduction in these 2 cell lines (Figure 7B).
Discussion
In this study, we demonstrate that capsid antigen presentation 
is dramatically inhibited by drugs that neutralize acidification 
of the endosome/lysosome, interfere with proteasome-mediated 
degradation, or block Golgi protein transport after AAV vector 
transduction in AAV-permissive cells. Furthermore, we found that 
AAV capsid antigen presentation was related to protein degrada-
tion by proteases and TPPII. Additional studies using well-char-
acterized AAV capsid mutants have demonstrated that the inabil-
ity of virions to escape from the endosome/lysosome resulted in 
decreased antigen presentation. Low antigen presentation was 
also observed using intact empty particles, whereas differential 
antigen presentation was observed when NLS/BR mutants (BR1, 
BR2, and BR3) were utilized.
The results of this study clearly show that the AAV capsid is pro-
cessed by AAV2-permissive cells through an endosomal/cytosolic 
pathway (11). Exogenous antigen can be processed and presented 
via 2 main pathways: endosomal and cytosolic. Endocytosis is the 
primary approach used by AAV to transduce target cells. If the 
AAV2 virion can cross the endosomal/lysosomal barrier, antigen 
cytosolic processing will follow. If not, antigen processing will 
be completed within endosomes or lysosomes, and the peptides 
generated from protease degradation will bind to recycled MHC 
class I molecules to be presented on the cell surface. In light of 
this observation, a previous study showed that AAV particles can 
be found in endosomal vesicles shortly after AAV infection, and 
the lysosomotropic agents ammonium chloride and bafilomycin 
A1 prevent AAV-mediated transduction (26). In the present study, 
we demonstrate that the acidification inhibitors ammonium chlo-
ride and chloroquine blocked AAV capsid antigen presentation, 
suggesting that vacuolar acidification is involved in AAV capsid 
antigen processing. However, additional studies have determined 
that proteasomal transport via the Golgi complex is required to 
process AAV particles and involves steps belonging to the cytosolic 
processing pathway (Figure 3). The data strongly suggest that 
capsid antigen presentation by AAV-transduced hepatocytes is 
proteasome dependent, given the need for acidification to allow 
AAV particle entry into the cytosol from the endosome/lysosome 
and for complete inhibition of AAV capsid antigen presentation 
by blocking proteasomal degradation. This conclusion is also in 
agreement with the fact that AAV antigen presentation is inhib-
ited in the presence of BFA, which impedes protein transport 
(including nascent MHC class I molecules) from the ER, without 
affecting the recycling of MHC class I molecules in endosomes and 
lysosomes. These data also indicate that AAV2 capsid antigen is 
presented by newly synthesized MHC class I molecules.
Although AAV2 capsid antigen presentation is not endosome 
dependent via recycling MHC class I molecules, partial inhibition 
of AAV2 capsid processing and presentation was observed with the 
protease inhibitors pepstatin H and leupeptin A, suggesting that 
proteolytic degradation in the endosome-lysosome system could 
Figure 7
Inhibition of capsid antigen cross-presentation with proteasome inhib-
itor in 293 and Cos7 cells. (A) Toxicity of bortezomib on 293/H-2Kb 
and Cos-7/H-2Kb cells. 293/H-2Kb cells (2 × 105 cells) or Cos-7/H-2Kb 
cells (2 × 105 cells) were seeded in 24-well plates and incubated with 
bortezomib. Cell viability was measured 24 hours later. (B) Effect of 
bortezomib on AAV2 transduction in 293/H-2Kb cells and Cos-7/H-2Kb 
cells. 293 cells or Cos-7 cells were incubated with inhibitors for 1 hour, 
and then 1 × 104 particles per cell of AAV2/luc vector were added to 
the culture and cells were incubated for 24 hours, then harvested for 
luciferase analysis. *P < 0.05 when compared with AAV2 without borte-
zomib treatment. (C) Effect of bortezomib on antigen presentation. After 
293/H-2Kb cells or Cos-7/H-2Kb cells were incubated with bortezomib 
for 1 hour, they were treated with 2 × 1010 AAV2-OVA/AAT vector for 
24 hours, then fixed with 1% paraformaldehyde and washed. Next, 
OT-1 spleen cells were added to HepG2/H-2Kb cell culture medium. 
Activation of OT-1 spleen cells was determined by flow cytometry for 
detection of CD8 and CD69 expression (C). **P < 0.01 when compared 
with AAV2-OVA without bortezomib treatment. Data represent the aver-
age of 3 individual experiments and SD.
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be important in the initial steps of AAV2 virion degradation. It is 
interesting to speculate that proteolytic degradation allows AAV2 
VP1 exposure on the virion surface, which in turn helps virions 
escape from the endosome/lysosome. It should not be overlooked 
that proteolytic degradation of the AAV capsid mediated by 
proteases could also occur in the autophagosome. Autophagy is 
a fundamental catabolic process that allows cells to recycle nutri-
ents and maintain the quality and quantity of cellular cytoplas-
mic components (47). This process of self-digestion is essential 
for homeostasis, development, and differentiation in eukaryotic 
cells. During autophagy, a double-membrane vesicle, the autopha-
gosome, is formed, which sequesters organelles, proteins, or parts 
of the cytoplasm, and fuses with the lysosome to degrade these 
intracellular components. Recently, autophagy has been proposed 
as another possible mechanism for antigen cross-presentation, 
especially for tumor antigen vaccine studies (48, 49), and it has 
been suggested that autophagy enhances classical MHC class I 
antigen presentation both in vitro and in vivo. In addition to its 
participation in antigen presentation of endogenous proteins by 
MHC class I molecules, autophagy may also be involved in antigen 
cross-presentation (49–51). After AAV infection, it is possible that 
AAV virions localized within organelles (e.g., Golgi, ER, microtu-
bule organizing center [MTOC]) are sequestered by autopha-
gosomes and degraded by proteases. The degraded AAV capsid 
peptides could then be delivered to the proteasome for further 
trimming to generate CTL epitopes, which bind to MHC class I 
molecules in the ER and present on the cell surface for CTL recog-
nition. Continuing refinement of the role of autophagy in normal 
cell homeostasis should facilitate a better understanding of how 
these cellular processes contribute to virus-host interaction.
In the current paradigm, AAV2 transduction is initiated by 
capsid binding to HSPG as a primary receptor, followed by inter-
action with coreceptors (19–24). After binding, AAV2 is postulated 
to enter the target cells via receptor-mediated endocytosis into the 
acidic compartments in a clathrin- and dynamin-dependent pro-
cess and travel to a perinuclear vesicle (25, 26). Acidification of the 
endosomal/lysosomal compartments is critical for effective AAV2 
infection, and various domains within AAV capsids contribute to 
differential roles in endosomal escape and nuclear transport. For 
example, the catalytic activity of a PLA domain on the VP1 N-ter-
minus is required for AAV2 infection. This domain is normally 
buried inside the AAV2 virion (27), however, during AAV2 infec-
tion, the PLA domain becomes exposed and its catalytic activity 
can now participate in endosomal release (27). Mutation of the 
PLA domain results in the loss of AAV2 infectivity, with defective 
trafficking of the AAV2 virion into the nucleus (27, 30). In this 
study, we also demonstrate that mutation of the PLA domain 
reduced AAV2 capsid antigen presentation, further supporting 
our pharmacological results which showed that the endosomal 
pathway is not the major mechanism for AAV capsid antigen 
cross-presentation after transduction.
In addition to the PLA domain, 3 NLS motifs (termed BR1, BR2, 
and BR3) with hydrophilic basic amino acid sequences in AAV2 
capsid protein have been shown to play a critical role in AAV traf-
ficking (29–31). Mutations in these capsid regions decrease AAV 
transduction. In this study, we examined the antigen presentation 
capacity of these mutants. Surprisingly, BR1 mutants generated 
less antigen presentation than wild-type AAV2, however, similar 
efficiency of antigen presentation was found among BR2 and BR3 
mutants (defective for nuclear entry) and wild-type AAV2. This 
finding is different from that of the transduction efficiency of 
these mutants, in which BR1 mutants initiated higher transgene 
expression (4-fold lower than wild-type AAV2) than either the BR2 
or BR3 mutants (100- and 2,000-fold lower than wild-type AAV2, 
respectively) (Figure 5). While the mechanism for these opposing 
phenomena is unclear, it is possible that the BR1 region mutant 
interferes with AAV2 capsid ubiquitination and decreases capsid 
degradation mediated by the proteasome. Alternatively, BR1 
mutants de-route and target the Golgi complex, avoiding AAV2 
capsid degradation (30). On the other hand, BR2 and BR3 mutants 
display a diffuse localization within the cytosol and may be more 
easily accessed by the ubiquitin-proteasome system (30). Since 
both BR2 and BR3 mutants are defective in nuclear transport, it 
can be concluded that nuclear entry by the AAV virion and uncoat-
ing in the nucleus are not necessary for effective capsid antigen 
cross-presentation. Whether antigens from uncoated capsids in 
the nucleus can be properly processed and presented warrants fur-
ther investigation. Even though antigen presentation by capsids 
uncoated in the nucleus occurs, the efficiency is likely low com-
pared with that of antigen from cytosol. Additionally, considering 
the high antigen presentation to low transgenic expression in BR2 
and BR3 mutants, it seems that the AAV genome derived from 
virion uncoating in the cytoplasm is not permissive to entry into 
the nucleus and the subsequent induction of transgenic expres-
sion. These results further indicate that AAV virion uncoating 
occurs in both the nucleus and the cytoplasm.
During AAV production, a critical concern for clinical trials is 
the contamination of vector particles lacking a genome, espe-
cially when using purification approaches with column chroma-
tography (45, 46). These empty virions substantially increase the 
dose of AAV capsid proteins and possibly result in an unwanted 
immunological response and decreased transgenic expression. 
Although empty AAV2 virions contain all components required 
for trafficking as full particles, including PLA2 and NLSs, capsid 
antigen presentation was nonetheless reduced in HepG2/H-2Kb 
cells infected with AAV2-empty virions compared with that in full 
particles. Although the fate of empty capsids in infected cells is not 
clearly known, the phenomenon of defective antigen presentation 
by AAV2-empty viruses may be interpreted as insufficient escape 
of these empty virions from the endosome. This interpretation is 
based on our previous study showing that AAV2-empty particles do 
not efficiently travel to the nucleus and are deficient in VP1 expo-
sure (30). A recent study using cryoelectron microscopy and image 
reconstruction demonstrated that during packaging of the AAV 
genome, the AAV capsid experiences continuous conformational 
changes (52). It is possible that the conformational changes medi-
ated by encapsidation of the AAV genome in full particles have a 
significant impact on exposure of the PLA domain on target cells 
during AAV infection. Three possibilities may account for the lack 
of effect of wild-type full particles from AAV2 virions on increasing 
antigen presentation by empty capsids. First, as described above, 
empty particles are unable to escape from endosomes. Second, 
there could be competition among the AAV transduction path-
ways, including receptor-binding competition between full parti-
cles and empty capsids, as was seen through inhibition of antigen 
presentation by AAV2-OVA full particles when coincubated with 
wild-type AAV2. A third option could be defective uncoating of 
empty AAV capsids in the cytosol. If empty virions are still intact 
in the cytosol, then the inability to present antigen would be con-
sistent with published studies showing that intact virions are 
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resistant to ubiquitination. If this is true, it suggests that expo-
sure of the VP1 N-terminus is necessary for effective AAV uncoat-
ing and capsid degradation, consistent with published studies of 
AAV trafficking and LPA mutants. Since our experiments were 
performed in vitro over a relatively short period (24–48 hours) 
with respect to in vivo transduction (weeks), these studies may not 
reflect all the alternative capsid antigen processes that can take 
place over extended periods (e.g., empty capsids may be processed 
and presented over time after AAV transduction due to consistent 
interaction of these virions with protease in endosomes and/or 
cytosol). It should be noted that our finding of decreased anti-
gen presentation by empty virions is inconsistent with a prior 
observation in which AAV2-empty pulsed target cells were killed 
by AAV capsid–amplified PBMCs (53). In the prior study, hetero-
geneous cell populations (NK, T cells) in PBMCs were used, and 
there was no negative control to determine whether cells without 
AAV2 infection were killed by AAV2-amplified PBMCs. There-
fore, it is difficult to rule out the possibility of NK cell–mediated 
cytotoxicity. This possibility is supported by an antigen dose-re-
sponse study in the same paper, where increased concentration of 
peptide resulted in higher CTL-mediated killing, but not for cells 
that were exposed to increased AAV vector doses (53).
The AAV virion is composed of 3 structural proteins: VP1, VP2, 
and VP3, with an approximate ratio of 1:1:8. It is unclear whether 
each virion contains the same ratio of 3 capsid proteins, or some viri-
ons contain only VP3. We show herein that antigen presentation by 
VP3-only virion is reduced compared with that by full, intact AAV2 
particles, and this is consistent with the fact that VP3-only virions are 
deficient for endosomal escape due to a lack of PLA and NLSs (30).
In our previous study, we demonstrated that a strong cellular 
immune response could be elicited from AAV2 vector–pulsed 
DCs in mice, although no transgenic expression was observed 
in these cells (9). This finding provided obvious evidence that 
capsid antigen could be effectively processed and presented on 
the surface of APCs. It is unclear whether the intracellular path-
ways used by APCs for AAV capsid antigen processing and pre-
sentation are similar to those used by AAV2-permissive cells such 
as 293, Cos7, and HepG2.
In this study, we demonstrate that AAV2 capsid antigen cross-pre-
sentation is dependent on proteasome-mediated capsid degrada-
tion. This observation has very important clinical implications 
for the utilization of proteasome inhibitors: suppression of AAV 
capsid antigen presentation and enhancement of transgene expres-
sion from AAV transduction (15, 54). It has been demonstrated that 
proteasome inhibitors increase AAV transduction in vitro and in 
vivo (15, 38, 54). The observation that bortezomib may influence 
AAV transduction as well as antigen presentation will be of signifi-
cant importance when designing clinical studies using AAV vectors.
In a patient with hemophilia B, CTL-mediated elimination of 
transduced cells was observed at a later time point (4 weeks) after 
AAV delivery (1). Clinical studies have demonstrated that the elim-
ination of transduced cells was not induced by transgene-specific 
(F9-specific) CTLs, but strongly suggested that AAV capsid–spe-
cific CTL response contributed to the therapeutic failure in this 
patient. We and others have suggested another possibility, which 
is that CTL response elicited from F9 cDNA alternative ORFs may 
be responsible for the clearance of AAV-transduced cells (33). CTL 
response detected in clinical trials was noted 4 weeks after infec-
tion, but results from this study show that antigen presentation by 
AAV2 capsid is dependent on the proteasome-mediated capsid deg-
radation that occurs within the first 48 hours. It remains unknown 
why antigen from capsids in human hepatocytes are potentially 
presented very late after AAV transduction, and more importantly, 
it is unclear which pathway for this antigen cross-presentation is 
Figure 8
Putative model of AAV2 capsid antigen cross-presen-
tation in AAV-transduced cells. Following binding on 
the cell surface in permissive cells via receptors and 
coreceptors, an AAV2 virion is uptaken by endocytosis 
into endosomes and lysosomes. PLA2 and NLSs are 
exposed on the virion surface to help the AAV virion 
escape into the cytosol. This is followed by AAV2 capsid 
ubiquitination and degradation by the proteasome. 
Resulting peptides are transported to the ER by TAP to 
bind MHC class I molecules. This complex is then traf-
ficked to the cell surface via the Golgi network for recog-
nition by capsid-specific CTLs. AAV2 virions also may 
travel to the Golgi complex and MTOC after endosomal/
lysosomal escape. These organelles are then seques-
tered by the autophagosome and delivered to protea-
somes for capsid antigen processing, or AAV2 virions 
are released from the Golgi complex and the MTOC into 
the cytoplasm for proteasomal degradation. Additionally, 
uncoated AAV2 capsid may enter the proteasome after 
the AAV2 virion enters the nucleus. Solid line indicates 
the pathways from the prior studies and this study. Dot-
ted line suggests possible routes for AAV2 capsid anti-
gen processing and presentation.
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Lentivirus vector pTK642/kb was constructed 
by insertion of the blunted H-2Kb fragment cut 
with EcoRI from pCBA-K2-kb into the HpaI site 
of pTK642. Endonuclease digestion and DNA 
sequencing were used to verify the clones.
Virus production. Recombinant AAV or lenti/ 
H-2Kb was produced as described before in HEK-
293 cells (55). Briefly, for production of AAV, poly-
ethylenimine (Sigma-Aldrich) was used for triple 
transfection of the pXR2 cap and rep plasmid, the 
pXX6-80 Ad helper plasmid, and the pTR-Luc or 
pTR-AAT reporter plasmids containing either 
luciferase or human alpha-1 antitrypsin trans-
genes flanked by inverted terminal repeats, respec-
tively. Sixty hours later, 293 cells were harvested 
and virus was purified by cesium chloride gradient density centrifugation. 
Virus was dialyzed against PBS and titered by dot-blot hybridization.
HIV-1–based vectors were generated using a transient 3-plasmid transfec-
tion approach with the standard calcium phosphate protocol (56). Briefly, 
vector constructs (15 μg), vesicular stomatitis virus glycoprotein envelope 
expression cassette (5 μg), and ΔNRF packaging cassettes (10 μg) were trans-
fected into 293T cells. Lentiviral particles were collected from conditioned 
medium 60 hours later. Lentivirus stocks were aliquoted and stored at –80°C.
Cells. The hybridoma TIB139 was used to produce a monoclonal anti-
body against H-2Kb (ATCC). HepG2/H-2Kb and 293/H-2Kb cell lines were 
established by transduction with lenti/H-2Kb in the presence of blasticidin 
S (InvivoGen). After transduction with lenti/H-2Kb, cells were incubated in 
medium with 10 μg/ml of blasticidin S. Blasticidin S–containing medium 
was replaced every 3–4 days. After 20 days of culture with blasticidin S, cells 
were serially diluted into 96-well plates at 1 cell per well and incubated in 
the presence of 50 μg/ml of blasticidin S. A single colony was transferred to 
a 10-cm dish to establish the stable cell lines. H-2Kb expression on the cell 
lines was verified by flow cytometry. Cells were incubated with medium from 
TIB139 culture for 1 hour at 4°C, and then washed. PE-conjugated rat anti-
mouse Ig secondary antibody (BD Biosciences – Pharmingen) was added for 
30 minutes at 4°C. Then the cells were washed and applied for cytometric 
analysis (Supplemental Figure 1). Cos7/H-2Kb cells were provided by N. 
Shastri (University of California, Berkeley, California, USA). All cells were 
maintained at 37°C and 5% CO2 in DMEM that was supplemented with 
10% heat-inactivated FCS, 100 U/ml penicillin, and 100 g/ml streptomycin.
Peptides. Peptides SIINFEKL (OVA 257-264) and p18 (F9 ARF1 18-26) 
(34) were synthesized at the Microprotein Sequencing and Peptide Syn-
thesis Facility at the University of North Carolina, and were 90% pure. Pep-
tides were reconstituted with DMSO at a concentration of 10 mg/ml and 
stored at –20°C.
Mice. The OT-1 mouse is transgenic for an H-2Kb–restricted T cell recep-
tor that recognizes the SIINFEKL peptide of OVA bound by H-2Kb (Tac-
onic Farms). All mice were maintained in a specific pathogen-free facil-
ity at the University of North Carolina at Chapel Hill. The University of 
North Carolina’s IACUC approved all procedures for this study. Single 
spleen cells from OT-1 were obtained by grinding the spleen against a cell 
strainer. The red blood cells were lysed with lysis buffer (Sigma-Aldrich). 
After washing twice, the spleen cells were used for incubation experiments 
with AAV-transduced target cells.
Cell cytotoxicity assay. Cell viability with drug treatment was determined 
using the CellTiter-Glo Luminescent Cell Viability Assay kit (Promega). 
HepG2/H-2Kb cells (2 × 105) in 300 μl of culture medium were incubated 
with drugs at indicated concentrations in 12-well plates for 24 hours. 
Three hundred microliters of CellTiter-Glo Reagent (Promega) was added 
to each well and mixed for 2 minutes on an orbital shaker to induce cell 
utilized. It is possible that both pathways (endosomal and pro-
teasomal) of capsid antigen cross-presentation are involved in 
humans, however, the data derived from this in vitro study strongly 
suggest that further research using in vivo models may be required 
to elucidate this novel mechanism of capsid antigen cross-presen-
tation after long-term AAV transduction in human liver.
According to results from AAV2 trafficking and data from this 
study, and as shown in Figure 8, we propose a putative model of 
AAV capsid antigen presentation by AAV-permissive cells. After 
cell surface binding and endocytosis, the AAV2 virion undergoes 
a conformational change in the endosome caused by an acidified 
environment. This process occurs in cooperation with the encapsi-
dated AAV genome and/or proteases to expose PLA2 and NLS 
motifs on the virion surface for endosomal escape and trafficking 
to the nucleus. Virus that is ubiquitinated in the cytosol is deliv-
ered to proteasomes for degradation and generation of epitopes 
that bind to MHC class I molecules to form an MHC-I-peptide 
complex to present on the cell surface via the Golgi secretory path-
way. TPPII is also involved in AAV capsid antigen processing either 
before or after AAV2 capsid degradation by the proteasome. Other 
organelles may be involved in AAV2 capsid antigen cross-presen-
tation, thus after the AAV2 virion travels to the Golgi complex or 
the MTOC, an autophagosome may sequester these organelles 
and have them degraded by proteases. After further trimming of 
capsid peptides in the proteasome, the antigens are transported 
to the ER for loading onto MHC I molecules. Uncoated capsid in 
the nucleus may also be transferred to the proteasome for further 
degradation to generate peptides for antigen presentation.
In conclusion, AAV2 capsid antigen presentation requires endo-
somal escape and is proteasome dependent in AAV2-permissive 
cells. Also, encapsidation of the AAV genome is required, but 
uncoating in the nucleus is not necessary for effective cross-pre-
sentation. The results from this study will aid the research on 
effective approaches to avoid capsid-specific CTL-mediated elimi-
nation of AAV2-transduced target cells in future clinical trials.
Methods
Construction of recombinant plasmids. pXR2OVA, pXR2/AN75HD, and 4 BR 
mutant plasmids (pXR2-BR1OVA, pXR2-BR2, pXR2-BR3, and pXR2-VP3) 
were described in our previous studies (29, 30, 33). To make pXR2-BR1OVA, 
pXR2-BR2OVA, pXR2-BR3OVA, pXR2-VP3OVA, and pXR2/AN75HD-
OVA, pXR2OVA was digested with XcmI and NotI to generate the fragment 
containing OVA SIINFEKL peptide nucleotide sequences. The fragment 
was cloned into pXR2-BR1, pXR2-BR2, pXR2-BR3, pXR2-VP3, and pXR2/
AN75HD-OVA by substituting the domain with XcmI and NotI digestion. 
Table 1
Function and working concentration of inhibitors
Inhibitor Function Working concentration
Chloroquine Prevents endosomal acidification 100 μM
Ammonium chloride Same as chloroquine 20 mM
Leupeptin Inhibits serine and cysteine proteases 50 ng/ml
Pepstatin Inhibits aspartate proteases 50 ng/ml
MG132 Blocks proteasomal activity 10 μM
Bortezomib Same as MG132 10 μM
Brefeldin A Prevents transport of ER resident MHC I  5 μg/ml 
 molecules on the cell surface
AAF-CMK Inhibits TPPII 500 ng/ml
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The drug concentrations used in this study for all inhibitors were not 
toxic during a 24-hour culture period (Table 1 and Figure 3).
For antigen presentation analysis in HepG2/H-2Kb cells transduced 
with AAV2 mutants, VP3-only, or AAV2-empty virions, HepG2/H-2Kb 
cells were transduced with these viruses for 24 hours, then washed and 
incubated with OT-1 spleen cells for another 24 hours. T cell activation was 
determined by flow cytometry.
Statistics. A 2-tailed Student’s t test was used to compare means. A P value 
less than or equal to 0.05 was considered significant. All data were analyzed 
using Excel software (Microsoft).
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lysis. The plate was allowed to incubate at room temperature for 10 min-
utes to stabilize luminescence signals. Luminescence was recorded with a 
Wallac 1420 Victor2 (PerkinElmer) automated plate reader.
Luciferase assay. HepG2/H-2Kb cells were plated in 24-well plates at 
a density of 105 cells per well. Twenty-four hours after inoculation with 
AAV at 104 particles per cell, the cells were lysed with passive lysis buffer 
(Promega). Luciferase activity was measured with a Wallac 1420 Victor2 
(PerkinElmer) automated plate reader.
Antigen presentation assay. HepG2/H-2Kb, 293/H-2Kb, or Cos7/H-2b cells 
(2 × 105) were treated with inhibitors (Table 1) for 1 hour and then infected 
with 2 × 1010 particles of AAV2-OVA/AAT or AAV2/AAT virus for 24 hours 
at 37°C, and 5% CO2 in DMEM with 10% heat-inactivated FBS, 100 U/ml 
penicillin, and 100 g/ml streptomycin. Then cells were fixed with 1% 
paraformaldehyde for 15 minutes at room temperature and washed 4 times 
using PBS with 3% FBS. Fixed AAV-transduced cells were incubated with 
spleen cells from OT-1 mice for 24 hours. Cells were then harvested and 
washed, and PE-labeled rabbit anti–mouse CD69 antibody (BD Biosciences – 
Pharmingen), along with an anti–CD8-FITC antibody (BD Biosciences – 
Pharmingen), were added for 1 hour at 4°C. OT-1 spleen T cell activation was 
analyzed by flow cytometry for CD69 expression (an early marker for activated 
T cells). The efficiency of antigen presentation inhibition was calculated by:
[1 – (number of activated OT-1 cells in inhibitor group with AAV2-
OVA infection – background group without AAV2-OVA infection)/
(number of activated OT-1 cells in group with AAV2-OVA infection – 
background group)] × 100%.
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